Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05929677 · ClinicalTrials.gov registry record · Early Phase 1

Impulsivity Domains and Subjective Response

A Early Phase 1 study of Alcohol Use Disorder, sponsored by Jessica Weafer.

Recruiting
Registry status
Early Phase 1
Development phase
250
Enrollment target
2
Study locations

NCT05929677 is a Early Phase 1 study of Alcohol Use Disorder that is actively recruiting participants, run by Jessica Weafer. The registered enrollment target is 250 participants, below the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (24% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05929677, a Early Phase 1 study of Alcohol Use Disorder, is actively recruiting participants, sponsored by Jessica Weafer.

RECRUITING
Registry status
Early Phase 1
Development phase
250 participants
Enrollment target
2
Study locations

Study Summary

Findings from this project will determine the relationship between two vulnerability factors for Alcohol Use Disorder (AUD) in young adults: impulsivity and subjective response to alcohol. The results will identify badly needed, novel targets for prevention and treatment efforts to simultaneously reduce impulsivity and subjective responses in at-risk young adults.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Alcohol

Study Locations (2)

Massachusetts

  • Northeastern University - Boston

Ohio

  • Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2024-04-01
Est. Completion 2027-09-01
Phase Early Phase 1

Sponsor

Jessica Weafer

4 total trials

What the Registry Record Tells You About NCT05929677

The ClinicalTrials.gov registry entry for NCT05929677 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (24% lower). The listed sponsor is Jessica Weafer, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05929677 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Ohio.

Frequently Asked Questions

What is clinical trial NCT05929677 about?

NCT05929677 is a clinical study titled "Impulsivity Domains and Subjective Response". Findings from this project will determine the relationship between two vulnerability factors for Alcohol Use Disorder (AUD) in young adults: impulsivity and subjective response to alcohol. The results will identify badly needed, novel targets for prevention and treatment efforts to simultaneously re...

What is the current status of trial NCT05929677?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 250 participants. The study started on 2024-04-01. Estimated completion is 2027-09-01.

What conditions does trial NCT05929677 study?

This clinical trial studies the following conditions: Alcohol Use Disorder.

What interventions are being tested in trial NCT05929677?

The interventions under investigation include: Placebo (DRUG), Alcohol (DRUG).

Who is sponsoring clinical trial NCT05929677?

This trial is sponsored by Jessica Weafer, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05929677 being conducted?

This trial has 2 study locations across Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.